

## Synairgen plc

('Synairgen' or the 'Company')

## Posting of Annual Report and Accounts and Notice of Annual General Meeting

---

**Southampton, UK** – 6 June 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that the Annual Report and Accounts for the year ended 31 December 2021 and Notice of its 2022 Annual General Meeting (AGM) were posted to shareholders today. These documents are available on the Company's website at [www.synairgen.com](http://www.synairgen.com).

### Annual General Meeting

Synairgen will host its AGM at 9:00 am BST on 30 June 2022 at Fieldfisher LLP, 9<sup>th</sup> Floor, Riverbank House, 2 Swan Lane, London, EC4R 3TT. The AGM will be held in person only.

Shareholders who are unable to attend the AGM but would like to exercise their right to vote on the resolutions being proposed should complete and submit an online proxy form to our registrar, Link Group, using their Signal shares online portal, by no later than 9:00 am BST on 28 June 2022. The form can be accessed and submitted at: [www.signalshares.com](http://www.signalshares.com). If shareholders require any assistance in completing a proxy form, they should refer to the details set out in the AGM Notice.

The results of voting on all resolutions at the AGM will be announced via a Regulatory Information Service and the full results of the voting published on the Company's website, in the usual way, as soon as practicable after the conclusion of the AGM.

### For further enquiries, please contact:

#### Synairgen plc

Brooke Clarke, Head of Communications

[Media@synairgen.com](mailto:Media@synairgen.com)

Tel: + 44 (0) 23 8051 2800

#### finnCap (NOMAD and Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Sunil de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

**Numis Securities Limited (Joint Broker)**

James Black, Freddie Barnfield, Duncan Monteith  
Tel: + 44 (0) 20 7260 1000

**Consilium Strategic Communications (Financial Media and Investor Relations)**

Mary-Jane Elliott, Jessica Hodgson, Namrata Taak  
[cscsynairgen@consilium-comms.com](mailto:cscsynairgen@consilium-comms.com)  
Tel: +44 (0) 20 3709 5700

**MKC STRATEGIES, LLC (US Media Relations)**

Mary Conway  
[MConway@MKCStrategies.com](mailto:MConway@MKCStrategies.com)  
Tel: +1 516-606-6545

**Notes for Editors****About Synairgen**

Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of severe viral lung infections, including COVID-19, as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA). Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see [www.synairgen.com](http://www.synairgen.com).